Cellectis
430 East 29th Street / New York, NY
8 rue de la Croix Jarry / 75013 Paris
2500 Sumner Boulevard / Raleigh, NC
United States
Website: http://www.cellectis.com/
69 articles about Cellectis
-
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
6/28/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders meeting, Axel-Sven Malkomes and Donald Bergstrom, M.D., Ph.D., have been appointed as Directors of the Company’s Board of Directors, effective immediately.
-
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
5/23/2022
Cellectis announced that it will hold its combined general meeting on June 28, 2022 at 2:30 p.m. CET at the Company's offices at 8 rue de la Croix Jarry 75013 Paris, France.
-
The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
-
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
5/16/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), today will present its first research data on the development of a novel universal CAR T-cell with immune-evasive properties using TALEN®-gene editing, at the American Society of Cell and Gene Therapy Annual Meeting (ASGCT) being held on May 16-19, 2022.
-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
5/12/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the three-month period ending March 31, 2022.
-
Cellectis to Report First Quarter 2022 Financial Results
5/5/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31st, 2022, on Thursday, May 12th, 2022, after the close of the US market.
-
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
5/5/2022
Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results for Calyxt’s first quarter ended March 31, 2022.
-
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
4/28/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), announced the publication of two manuscripts in Nature Communications on its product candidate UCART123, currently being evaluated in the Phase 1 dose-escalation trial AMELI-01 in patients with relapsed or refractory acute myeloid leukemia (r/r AML).
-
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
4/27/2022
Cellectis announces that its partner Cytovia Therapeutics, LLC, a biopharmaceutical company empowering natural killer cells to fight cancer through stem cell engineering and multispecific antibodies, entered into a definitive business combination agreement with Isleworth Healthcare Acquisition Corp., a Special Purpose Acquisition Company.
-
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
-
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
4/8/2022
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research Annual Meeting.
-
Cellectis to Participate in Two Upcoming Investor Conferences in March 2022
3/11/2022
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that management will participate in the Oppenheimer & Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17.
-
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
2/24/2022
Cellectis announced that it will report its financial results for the fourth quarter and year-end 2021 ending December 31, 2021, on Thursday, March 3, 2022, after the close of the US market.
-
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor Disclosure
2/18/2022
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. (“Calyxt”), a majority-owned (61.8% as of December 31, 2021) subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock.
-
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
2/10/2022
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), today announced the appointment of Bing C. Wang, PhD, MBA, as Chief Financial Officer and member of Cellectis’ executive committee.
-
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
1/10/2022
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials.
-
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
1/4/2022
Cellectis reported business objectives for its products pipeline and in-house manufacturing for 2022.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
12/11/2021
Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients at the 63rd Annual Meeting of the American Society of Hematology in Atlanta, Georgia.
-
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
11/12/2021
Cellectis S.A. announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin